Loading…
TEVA-RAMIPRIL is a brand name for Ramipril, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Serious Warnings and Precautions When used in pregnancy, angiotensin converting enzyme (ACE) inhibitors can cause injury or even death of the developing fetus. When pregnancy is detected Teva-Ramipril should be discontinued as soon as possible (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).
General Cough A dry, persistent cough, which usually disappears only after withdrawal or lowering of the dose of ramipril, has been reported. Such possibility should be considered as part of the differential diagnosis of cough (see ADVERSE REACTIONS).
g. g. operating a vehicle or machinery). 73 m2). Therefore, the use of Teva-Ramipril in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS). The use of Teva-Ramipril in combination with an ARB is contraindicated in patients with diabetic nephropathy (see CONTRAINDICATIONS).
Further, co-administration of ACE inhibitors, including Teva-Ramipril, with other agents blocking the RAS, such as ARBs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia (see DRUG INTERACTIONS).
Cardiovascular Aortic Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at 6 particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction.
Hypotension Symptomatic hypotension has occurred after administration of ramipril, usually after the first or second dose or when the dose was increased. , stenosis of the aortic valve) or in patients with hemodynamically relevant renal artery stenosis.
All patients should be cautioned about this potential excessive fall in BP and advised to consult their physician. Generally, it is recommended that dehydration, hypovolaemia or salt depletion be corrected before initiating treatment (in patients with heart failure, however, such corrective action must be carefully weighed against the risk of volume overload).
When these conditions have become clinically relevant, treatment with Teva-Ramipril must only be started or continued if appropriate steps are taken concurrently to prevent an excessive fall in BP and deterioration of renal function.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ramipril in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
In patients with ischemic heart disease or cerebrovascular disease, an excessive fall in BP could result in a myocardial infarction or cerebrovascular accident (see ADVERSE REACTIONS – Clinical Trial Adverse Drug Reactions). Because of the potential fall in BP in these patients, therapy with Teva-Ramipril should be started under close medical supervision.
Such patients should be followed closely for the first weeks of treatment and whenever the dose of Teva-Ramipril is increased. In patients with severe congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension and has been associated with oliguria, and/or progressive azotemia, and rarely, with acute renal failure and/or death.
9% sodium chloride. A transient hypotensive response may not be a contraindication to further doses which usually can be given without difficulty once the BP has increased after volume expansion in hypertensive patients. However, lower doses of Teva-Ramipril and/or reduced concomitant diuretic therapy should be considered.
Teva-Ramipril may lower the state of patient alertness and/or reactivity; particularly at the start of treatment (see ADVERSE REACTIONS). Patients should be cautioned to report lightheadedness, especially during the first few days of Teva-Ramipril therapy.
If actual syncope occurs, the patients should be told to discontinue the drug and consult with their physician. 7 mEq/L) was observed in approximately 1% of hypertensive patients in clinical trials treated with ramipril. In most cases, these were isolated values which resolved despite continued therapy.
Hyperkalemia was not a cause of discontinuation of therapy in any hypertensive patient. Risk factors for the development of hyperkalemia may include renal insufficiency, diabetes mellitus, and the concomitant use of agents to treat hypokalemia or other drugs associated with increases in serum potassium (see DRUG INTERACTIONS-Drug-Drug Interactions).
Hematologic Neutropenia/agranulocytosis Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. Several cases of agranulocytosis, neutropenia or leukopenia have been reported in which a causal relationship to ramipril cannot be excluded.
Current experience with the drug shows the […]